Лучшие больницы для «Peyronie's Disease Treatment» в Дели (NCR), Индия

Peyronie's Disease (PD) is a fibrotic disorder of the tunica albuginea—the dense fibro-elastic sheath encasing the erectile bodies—characterised by the formation of inelastic collagen plaques (predominantly Type III collagen replacing Type I) that disrupt penile biomechanics. The plaques create a tethering effect during erection, producing penile curvature (typically dorsal, ranging 30°–90°+), hourglass deformity, hinge defect, or shortening, and in moderate-to-severe cases cause penetration-impairing deformity, coital pain, and erectile dysfunction (ED) in up to 79% of affected men. The condition has an estimated prevalence of 3–9% in adult males, though real-world figures are likely higher due to under-reporting, and it is increasingly recognised in men aged 30–70, frequently following blunt or repetitive micro-trauma during intercourse.

• IDEAL SURGICAL CANDIDATES (Plaque Incision/Excision with Grafting or Plication):

- Stable Peyronie's Disease: curvature unchanged for ≥3 months (AUA definition of stability)

- Curvature ≥30° causing penetration difficulty or complete inability to have intercourse

Pharmacological / Minimally Invasive Therapies

1. Intralesional Collagenase Clostridium histolyticum (CCH / Xiaflex) The only FDA/EMA-approved pharmacotherapy. A standard treatment cycle consists of 2 injections administered 24–72 hours apart into the plaque, followed by penile modelling under physician guidance, repeated up to 4 cycles (8 injections total) at 6-week intervals. CCH selectively cleaves Type I and III collagen fibres within the plaque. The IMPRESS I & II pivotal trials demonstrated a mean curvature improvement of ~34% (vs. ~18% placebo) and significant PDQ bother score reduction. GAF partner centres use high-resolution ultrasound guidance for injection precision, reducing the risk of corporal injury. Penile traction therapy (PTT) with a validated device (FastSize, RestoreX) is initiated between injection cycles to augment length recovery and modelling effect.

2. Intralesional Verapamil (ILV) Calcium-channel blocker injected directly into the plaque (10 mg/10 mL in saline; biweekly for 6 months). Mechanistically inhibits fibroblast proliferation and stimulates collagenase activity, reducing plaque volume. Used primarily in active-phase disease or as an adjunct when CCH is unavailable or contraindicated. Response rates for curvature improvement are modest (~25–30%) but the safety profile is favourable.

3. Intralesional Interferon-α2b Biological agent that downregulates TGF-β1 and reduces fibroblast proliferation. Administered biweekly for 12 weeks; supported by RCT data showing curvature improvement and pain reduction. Considered when CCH is not accessible.

PRE-OPERATIVE / PRE-TREATMENT PHASE (Days 1–7 after arrival)

Day 1–2: Arrival & Consultation

• Airport transfer by GAF Healthcare coordinator; hotel or hospital guest house check-in
• Comprehensive andrology/urology consultation with review of all prior imaging and records sent in advance
• Baseline penile dynamic duplex ultrasound (PDDU) with pharmacological erection (intracavernosal alprostadil)
• Standardised erect penile photography with goniometric curvature measurement
• IIEF-5 and PDQ questionnaire administration
• Blood work: CBC, coagulation, metabolic panel, testosterone, HbA1c, PSA
• Anaesthesia fitness assessment (ECG, chest X-ray if indicated)